Medulloblastoma - 41 Studies Found
| COMPLETED |
: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers : Medulloblastoma : 2025-08-06 : Individuals will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total |